IRP Research Shows Benefits of More Intensive Treatments for Certain Patients
By Melissa Glim
Wednesday, September 28, 2022
Fate can be cruel, especially when it comes to a rare, highly fatal blood cancer called acute myeloid leukemia (AML). Even when months of intensive chemotherapy appear to cause a complete remission of the disease — meaning doctors cannot detect any remaining cancer cells in a patient’s body — roughly half of those patients see the cancer return within two years, or even as soon as six months. Sadly, most of them don’t survive their second bout with the disease.
As a medical student, IRP senior investigator Christopher Hourigan, M.D., D.Phil., thought this outcome was unfair. More than that, he thought it indicated that the standard ways doctors determined if an AML patient was in remission were inadequate, and that remission might not even be the right goal. That’s why he has focused his career on finding ways to detect, prevent, and treat AML recurrence, known in his field as ‘relapse’.
“I was a scientist before I became a doctor, and it was really eye-opening to me, when I started to practice medicine, how difficult some of the treatment decisions were and how limited the information available was to inform those decisions,” Dr. Hourigan says.
Dedicated Staff and Cutting-Edge Technology Helps Solve Pain’s Many Mysteries
By Brandon Levy
Thursday, May 5, 2022
For such a common ailment, pain remains a significant mystery. Part of the challenge of studying it is that it occurs in so many conditions and can vary from a mild ache to life-altering misery. Fortunately for both pain patients and IRP researchers studying pain, the NIH Pain Research Center has the technology and expertise to power new discoveries about pain in its many, complex forms.
On March 31 and April 1, NIH’s National Center for Complementary and Integrative Health (NCCIH) hosted a two-day virtual symposium titled “Tackling Pain at the National Institutes of Health: Updates From the Bench, the Clinic, and the New NIH Pain Research Center,” which featured presentations from a number of IRP scientists exploring important questions related to pain. Read on to learn more about some of the research discussed during that event, including efforts examining pain in patients with rare diseases, early-phase clinical trials of a new pain treatment, and investigations of how psychological factors can affect the way people experience pain.
Studies of Blood Stem Cells Stimulate Pioneering Therapeutic Approaches
By Melissa Glim
Wednesday, April 14, 2021
The National Academy of Medicine (NAM), first established in 1970 by the National Academy of Sciences as the Institute of Medicine (IOM), is comprised of more than 2,000 elected members from around the world who provide scientific and policy guidance on important matters relating to human health. Election to the NAM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have not only made critical scientific discoveries but have also demonstrated a laudable commitment to public service.
IRP Distinguished Investigator Cynthia E. Dunbar, M.D., was elected to the NAM last year for her pioneering research into hematopoietic stem cells, the cells in bone marrow that develop into oxygen-carrying red blood cells, infection-fighting white blood cells, and clot-forming platelets. Her work has led to valuable insights into the production of those blood cells, called hematopoiesis, and its role in human health. Her discoveries have also resulted in new approaches to treat disease by improving stem cell functioning or manipulating stem cells with gene therapy.
Unconventional Genetic Strategy Could Enhance Production of Medical Treatments
By Brandon Levy
Tuesday, March 23, 2021
We all have bad days on the job — your colleague keeps bugging you, your boss yelled at you for an innocent mistake, and you skipped lunch because you have 10 different deadlines coming up. Understandably, many people find it much harder to get their work done under such stressful circumstances. Microbes that produce chemicals for medicine and scientific research experience similar struggles, but a recent IRP study has found that short-circuiting their stress response makes them far more efficient at that task.
Program Boosts Initiatives Supporting Researchers Across NIH
By Brandon Levy
Tuesday, September 1, 2020
From Superbowl-winning football teams to comic book cohorts like The Avengers, combining the efforts of multiple talented individuals is a proven strategy for achieving remarkable results. It may come as no surprise, then, that the NIH’s Intramural Research Program (IRP) strongly encourages collaborations that breach the boundaries of its 24 Institutes and Centers. One example of these efforts is the Director’s Challenge Innovation Awards Program, which since 2009 has funded high-impact scientific projects that bring together researchers from across the IRP.
Scientific Team-Up Identifies Source of Tumor Drug Resistance
By Brooke Worthing
Tuesday, December 17, 2019
It’s an unfortunate reality that nearly everyone knows somebody whose life has been affected by cancer. However, a discovery by two researchers who met by chance years ago might one day help more cancer patients overcome their disease. Two scientific teams led by the IRP’s Craig Thomas, Ph.D., a group leader at the NIH’s National Center for Advancing Translational Sciences (NCATS), and Daniel Starczynowski, Ph.D., of Cincinnati Children’s Hospital Medical Center, recently published a study describing a possible breakthrough in the fight against acute myeloid leukemia (AML), a form of cancer responsible for nearly 11,000 deaths per year in the United States.
Exceptional Early-Stage Investigators Push the Boundaries of Translational Research
By Brandon Levy
Thursday, December 5, 2019
Online and print publications are constantly touting momentous discoveries by superstar scientists like CRISPR-Cas9 co-discover Jennifer Doudna or the IRP’s own Kevin Hall, who changed the way we think about weight loss. It can be easy to forget that today’s biomedical pioneers were once young researchers toiling to establish themselves in the competitive environment of modern science.
Each year, a small, exceptionally promising group of scientific up-and-comers become Lasker Clinical Research Scholars through a highly competitive program jointly funded by the NIH and the Albert and Mary Lasker Foundation. The program presents early-stage physician-scientists with the opportunity to carry out independent clinical research at the NIH for five to ten years. The 2019 class of Lasker Scholars consists of five extremely talented researchers who are now beginning a critical new phase in their careers. Let’s meet them.
By Michael Gottesman
Monday, May 21, 2018
James F. Holland, M.D., a renowned cancer expert who was a major figure in the development of cancer chemotherapy, died on March 22, 2018, at the age of 92. Dr. Holland was among the first group of research physicians recruited to the NIH Clinical Center, serving as a senior surgeon at the National Cancer Institute from 1953 to 1954. In that short year at the NIH, he initiated a clinical trial to compare continuous or intermittent treatment with two chemotherapy agents for acute leukemia in children: methotrexate and 6-mercaptopurine. Dr. Holland moved to Roswell Park Memorial Institute in Buffalo before the trial was completed, but he continued to collaborate. His work ultimately turned an incurable illness into one with an 80% survival rate. In 1972, he and his NIH collaborators shared the Albert Lasker Clinical Medical Research Award for "outstanding contribution to the concept and application of combination therapy in the treatment of acute leukemia in children."
By Lucy Bauer
Monday, April 27, 2015
One of the best parts of a new idea is being able to share it! Research is certainly no exception. On Thursday, April 30th, the postbacs of NIH will be sharing their ideas and findings at Postbac Poster Day.
By Michele Lyons
Friday, February 27, 2015
“Then we have ‘prevention is more important than cure.’ That’s the one I like best. That’s my pet peeve…."
Dr. Emil Freireich, NCI, in his 1997 oral history. Dr. Freireich helped develop combined chemotherapy for childhood leukemia.
